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1  | INTRODUC TION
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal neuro-
degenerative disease. This disorder is characterized by a progressive 
motor neuron (MNs) loss in brain and spinal cord, causing paralysis, 
respiratory failure and death within 5 years from the diagnosis.1 At 
molecular level, the DNA/RNA-binding protein TAR (trans-activation 
response element) DNA-binding protein (TDP-43) was described to 
be the major component of the pathological aggregates found in 
brains of ALS patients.2 The presence of the GGGGCC (G4C2)-repeat 
expansion in the noncoding region of the open reading frame 72 
(C9ORF72) gene on the chromosome 9 is the most frequent genetic 
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Abstract
As for the majority of neurodegenerative diseases, pathological mechanisms of 
amyotrophic lateral sclerosis (ALS) have been challenging to study due to the difficult 
access to alive patients' cells. Induced pluripotent stem cells (iPSCs) offer a useful in 
vitro system for modelling human diseases. iPSCs can be theoretically obtained by 
reprogramming any somatic tissue although fibroblasts (FB) remain the most used 
cells. However, reprogramming peripheral blood cells (PB) may offer significant ad-
vantages. In order to investigate whether the choice of starting cells may affect re-
programming and motor neuron (MNs) differentiation potential, we used both FB 
and PB from a same C9ORF72-mutated ALS patient to obtain iPSCs and compared 
several hallmarks of the pathology. We found that both iPSCs and MNs derived from 
the two tissues showed identical properties and features and can therefore be used 
interchangeably, giving the opportunity to easily obtain iPSCs from a more manage-
able source of cells, such as PB.
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cause of ALS and frontotemporal dementia (FTD). Usually, in healthy 
subjects, the number of G4C2-repeats is lower than 30 but con-
versely can be in the order of thousands in ALS/FTD patients. The 
C9ORF72 repeat expansion determines several pathological hall-
marks, among which there is a toxic gain of function of RNA repeats, 
accompanied by foci formation. No effective cure for this disease is 
yet available, mainly due to the fact that pathological mechanisms 
are difficult to study owing to the impossibility to obtain affected 
cells from alive patients. In addition, post mortem brain tissues rep-
resent only the end stage of the disease limiting the comprehension 
of cellular and structural defects leading to the onset of neurode-
generation. Studies to elucidate ALS pathological mechanisms have 
also been limited by the lack of models able to fully mimic affected 
MNs until the advent of induced pluripotent stem cells (iPSCs).3 This 
powerful in vitro model allows the generation of patient-specific cell 
lines that can be differentiated into MNs, affected in ALS. iPSCs can 
be obtained by reprogramming different cell types such as CD34+ 
cord blood cells,4 keratinocytes5 or peripheral blood (PB),6,7 but fi-
broblasts (FB) remain the most widely used.8-11 However, FB do not 
necessarily represent the best cell source to generate iPSCs, not even 
displaying the highest reprogramming efficacy and needing in vitro 
passages before reprogramming increasing the risk to accumulate 
genetic alteration. Additionally, if compared to PB, a biopsy punch 
is doubtless more invasive than a venipuncture. PB has been already 
shown to be an easily accessible source of patient tissue without the 
need to extensively maintain cells in culture prior to reprogramming 
experiments.6 Furthermore, using PB as starting source may allow 
to achieve longitudinal studies of the same patient over many years 
and easily create a bio-bank of collected samples. In this work, we 
investigated and compared the key aspects of iPSCs and iPSC-de-
rived MNs obtained from FB and PB of a C9ORF72-mutated patient.
2  | MATERIAL AND METHODS
This study was approved by the ethics committee of IRCCS Istituto 
Auxologico Italiano.
2.1 | Sample collection and processing
Skin biopsy and PB were collected from a 49 years old female affected 
by ALS and carrying a C9ORF72 repeat expansion. Written informed 
consent was obtained from the patient. FB were obtained from skin 
biopsy as follow: the skin tissue fragment was transferred in a 60 mm 
culture dish and subcutaneous residuals removed. Few drops of FB 
medium (RPMI 1640 (Euroclone) supplemented with 10% foetal bo-
vine serum (FBS, Sigma-Aldrich), 2 mmol/L l-glutamine, 2.5 μg/mL 
amphotericin B (Sigma-Aldrich), 100 U/mL penicillin and 100 μg/mL 
streptomycin) were added, and the sample was allowed to adhere to 
the bottom of the dish overnight. The following day, fresh medium was 
added and changed twice a week after attachment and outgrowth of 
cells from skin dissection. FB were maintained in medium and expanded 
at 37°C with 5% CO2. Reprogramming was performed by the fifth 
passage. Peripheral blood mononuclear cells (PBMCs) were isolated 
by layering diluted blood sample on a density gradient (1.077 g/mL) 
(Histopaque®-1077, Sigma-Aldrich) followed by centrifugation. PBMCs 
layered in the plasma-density medium interface were washed, counted 
and cryopreserved in FBS/10% DMSO until reprogramming.
2.2 | Reprogramming of iPSCs
iPSCs were obtained using the CytoTune®-iPS 2.0 Sendai 
Reprogramming Kit (Thermo Fisher Scientific) by adding the Klf4, 
Oct4, Sox2 and c-Myc virus, following manufacturer's instructions. 
Briefly, 2 days before reprogramming, FB were seeded in a well of a 
6-well plate in FB medium at 30%-60% confluence. After reprogram-
ming, they were maintained in FB medium until day 7 and therefore 
plated onto Matrigel (Corning) coated dishes to allow colony at-
tachment. For PB, 500 000 PBMCs were seeded in a 24-well plate 
and cultured with the addition of IL-3 (20 ng/mL), IL-6 (20 ng/mL), 
SCF (100 ng/mL) and FTL-3 ligand (100 ng/mL) (all from Gibco) in 
StemPro-34 medium (Thermo Fisher Scientific) for 4 days. The third 
day after transduction, cells were transferred on Matrigel-coated 
dishes and cultured in StemPro-34 without cytokines.
For both samples, the eighth day after reprogramming, medium 
was replaced with the iPSCs-specific Essential 8 medium (Thermo 
Fisher Scientific). Spent medium was daily replaced with fresh me-
dium and the cultures monitored for the emergence of iPSC colo-
nies. When colonies reached the appropriate size, six clones per 
sample were picked and transferred on new Matrigel-coated dishes 
for expansion. Colonies, passaged using an EDTA 0.5 mmol/L solu-
tion, were expanded in Essential 8 medium for at least six passages 
before being characterized and differentiated.
2.3 | Characterization of iPSCs clones
After at least six passages in culture, karyotyping and characteriza-
tion were performed on clones from each starting material.
2.3.1 | Karyotyping
Colcemid solution (KaryoMAX™, Thermo Fisher Scientific) was 
added overnight to cultured cells in logarithmic phase. Chromosomes 
were stained with the fluorescent dye quinacrine mustard (Sigma-
Aldrich). Q-Band stained chromosomes were analysed.
2.3.2 | Repeat primed PCR
The maintenance of repeat expansion was evaluated by repeat primed 
PCR as previously described.12 DNA was extracted from repro-
grammed cells using Wizard® Genomic DNA Purification Kit (Promega 
     |  3BARDELLI Et AL.
Corporation, Madison, WI). High-quality genomic DNA (200 ng) was 
amplified using three specific primers (1.4 µmol/L FAM forward 
primer, 0.7 µmol/L Reverse primer, 1.4 µmol/L Reverse Anchor M13 
primer [see Appendix S1]) and 180 µmol/L of deAZAdGTP/dNTPs 
mix (Roche). The PCR reaction was performed as here described: ini-
tial denaturation at 98°C for 10 minutes followed by 10 cycles of de-
naturation at 97°C for 35 seconds, annealing at 64°C for 2 minutes 
and extension at 68°C for 8 minutes. Subsequently, additional 25 cy-
cles with denaturation at 97°C for 35 seconds, annealing at 64°C for 
2 minutes and extension at 68°C for 8 minutes adding 20 seconds to 
each additional cycle were performed. After amplification, 1.5 µL of 
the PCR product was mixed with 15.5 µL Hi-Di™ Formamide (Applied 
Biosystems) and 0.5 µL GeneScan™ 500 ROX™ dye Size Standard 
(Applied Biosystems). The capillary electrophoresis was performed on 
the ABI 3500 Genetic Analyzer (Applied Biosystems), and output was 
analysed with Gene Mapper v.4 software (Applied Biosystem).
2.3.3 | Stemness evaluation
For reverse transcription (RT), total RNA was isolated from both 
iPSC clones and starting tissues using Trizol Reagent (Thermo 
Fisher Scientific) following manufacturer's instruction and reverse 
transcribed into cDNA using SuperScript II reverse transcriptase 
(Thermo Fisher scientific). Briefly, RT was primed with Oligo(dt) 
(Eurofins Genomics, Luxembourg, LU) and reaction incubated at 
42°C for 40 and 15 minutes at 70°C. Loss of SeV genome and viral 
transgenes was assessed by RT-PCR (denaturation 95°C 30 sec-
ond, annealing 54°C 30 second, elongation 72°C 1 minutes, for 
35 cycles) using commercial primers (Thermo Fisher Scientific, see 
Appendix S1). RT-PCR was then performed (denaturation 95°C 
30 seconds, annealing 60°C 30 seconds, elongation 72°C 1 min-
utes, for 35 cycles) to reveal expression of stemness markers, using 
the following primers: Sox 2, Oct 3/4 and Nanog (see Appendix S1).
For immunofluorescence, iPSCs cultured on coverslips were 
fixed in 4% paraformaldehyde (Santa Cruz Biotechnology) for 
20 minutes and permeabilized with 0.3% Triton X-100 (Sigma-
Aldrich). Cells were then incubated for 20 minutes in 10% normal 
goat serum (NGS) (Gibco) in PBS and primary antibodies added for 
90 minutes at 37°C. After two washes with 10% NGS in PBS, cells 
were stained with Alexa 488 and Alexa 555 conjugated secondary 
antibodies (Invitrogen, Thermo Fisher Scientific, Waltham, MA, 
USA). Nuclei were stained using 4′,6-diamidino-2-phenylindole, 
dihydrochloride (DAPI) (Sigma-Aldrich) and images acquired with a 
confocal microscope (Nikon Eclipse C1, Minato). The following pri-
mary antibodies were used: TRA-1-60 (1:125, Invitrogen), SSEA4 
(1:100, Invitrogen) and alkaline phosphatase (1:250, Abcam).
2.3.4 | In vitro spontaneous differentiation
Embryoid bodies (EBs) were generated by suspending iPSCs in low 
adhesion plates in HuES medium (DMEM/F12, 20% knock-out 
serum replacement, 2 mmol/L l-glutamine, 10 U/mL penicillin, 
10 μg/mL streptomycin, 0.1 mmol/L MEM NEAA, 110 μmol/L 
β-mercaptoethanol [all from Thermo Fisher Scientific]). After 
7 days, EBs were plated on Matrigel-coated coverslips and 
grown in Essential 8 medium for additional 10 days. Expression 
of the three germ layer-specific markers was evaluated by im-
munofluorescence (β III tubulin (1:500, Abcam) for ectoderm, 
desmin (1:10, Chemicon, Merck Millipore) for mesoderm and al-
pha-fetoprotein (1:125, Invitrogen) for endoderm) as previously 
described.
2.4 | Differentiation of iPSCs into neural stem cells 
(NSCs)
iPSCs were cultured in Induction medium (Neurobasal and 2% Neural 
Induction Supplement [Thermo Fisher Scientific]) for 7 days. On day 
eight, cells were harvested by Accutase (Euroclone) and seeded 
on Matrigel-coated dishes in Expansion medium (50% Neurobasal, 
50% DMEM/F12 and 4% Neural Induction Supplement) with addi-
tion of 10 μmol/L RHO-associated kinase (ROCK) inhibitor Y27632 
(Selleckchem). Cells were allowed to grow and expanded for at least 
five passages, until they showed a homogeneous neural morphology. 
Expression of NSCs-specific marker nestin (1:100, Chemicon) was 
assessed by immunofluorescence.
2.5 | Differentiation of iPSCs into MNs
MNs were differentiated as previously described.13 Briefly, iPSCs 
were grown in 100 mm dishes until confluence, harvested and 
placed into low adhesion dishes to generate EBs. Cells were grown in 
suspension for the first 2 days in HuES medium supplemented with 
20 ng/mL basic fibroblast growth factor (Peprotech) and 20 μmol/L 
ROCK in order to enhance single cell survival. Neuralization was 
induced starting from the third day by adding 10 μmol/L SB431542 
(Tocris) and 0.2 μmol/L LDN193189 (Sigma-Aldrich) to the culture. 
The fourth day, EBs were switched to neural induction medium 
(DMEM/F12, 2 mmol/L l-glutamine, 10 U/mL penicillin, 10 μg/mL 
streptomycin, 0.1 mmol/L MEM NEEA, 2 μg/mL heparin (Sigma-
Aldrich), 1% N2 supplement [Thermo Fisher Scientific]), supple-
mented with 20 μmol/L ROCK inhibitor, 0.4 μg/mL ascorbic acid 
(AA) (Sigma-Aldrich), 1 μmol/L retinoic acid (RA) (Sigma-Aldrich), 
10 ng/mL brain-derived neurotrophic factor (BDNF) (Peprotech). 
SB431542 and LDN193189 were added until day 7 when cultures 
were supplemented with 1 μmol/L smoothened agonist (Tocris) 
and 0.5 μmol/L purmorphamine (Sigma-Aldrich). EBs were grown 
for 10 days with a medium change every other day. For dissociation 
of EBs, on day 17, 0.05% trypsin (Sigma-Aldrich) was used and cells 
were plated on poly-lysine (Sigma-Aldrich)/laminin (Thermo Fisher 
Scientific)-coated coverslips in 24-well plates at a concentration 
of 5 × 105 cells/well. Cells were cultured in neural differentiation 
medium (Neurobasal, 2 mmol/L l-glutamine, 10 U/mL penicillin, 
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10 mg/mL streptomycin, 0.1 mmol/L MEM NEAA, 1% N2 sup-
plement), supplemented with 2% B27 (Gibco), 1 μg/mL laminin, 
25 μmol/L glutamate (Sigma-Aldrich), 0.4 μg/mL AA, 10 ng/mL 
glial-derived neurotrophic factor (GDNF) and 10 ng/mL ciliary neu-
rotrophic factor (CNTF) (both from Peprotech). MNs were fixed for 
immunofluorescence or used for RNA/protein extraction after 
10 days of differentiation. For immunofluorescence, the following 
MNs markers were used: β III tubulin, SMI312 (1:1000, Covance) 
and HB9 (1:100, DSHB, NIH) as previously described for the char-
acterization of iPSCs.
RT-PCR was performed as previously described to identify ex-
pression of Chat and HB9 markers (see Appendix S1).
2.6 | TDP-43 localization
Immunofluorescence analysis was performed as previously de-
scribed for the characterization of iPSCs and MNs, using an anti-
TDP-43-2AP (1:500, Proteintech) and an anti-phospho TDP-43 
(pS409/410) (1:200, Cosmobio) primary antibodies.
2.7 | Western Blot
Cells collected by centrifugation and washed with ice-cold PBS 
were lysed in lysis buffer (20 mmol/L Tris–HCl pH 7.5, 150 mmol/L 
NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton X-100, protease 
inhibitor cocktail [Roche]). Cell extracts were quantified using 
Pierce BCA protein assay (Thermo Fisher Scientific) and 20 μg pro-
tein separated by SDS-PAGE on 10% NuPAGE Bis-Tris pre-cast po-
lyacrylamide gels (Thermo Fisher Scientific) and then transferred 
to nitrocellulose membranes. Membranes were blocked with 5% 
(w/v) nonfat dry milk in Tris-buffered saline with Tween 20 (Sigma-
Aldrich) (TBST; 20 mmol/L Tris-HCl [pH 7.6], 0.1% Tween 20, 
137 mmol/L NaCl) for 1 hour. After blocking, membranes were incu-
bated with primary antibodies (TDP-43-2AP (1:1000) and GAPDH 
[1:2000, Santa Cruz]) in blocking solution overnight at 4°C. After 
three washes, membranes were incubated with secondary antibod-
ies (anti-mouse/rabbit HRP-conjugated, 1:10 000, both from Santa 
Cruz) for 1 hour at room temperature. The Novex ECL kit (Thermo 
Fisher Scientific) was used for detection of the HRP-conjugated 
secondary antibody. Densitometric analyses were performed using 
ImageJ software (NIH).
2.8 | RNA foci identification
RNA FISH was performed using 5′ a TYE-563-labelled locked nucleic 
acid (LNA) probe complementary to the sense RNA foci containing 
GGGGCC-repeats (Exiqon Qiagen, Hilden, DE). Cells were permea-
bilized with 0.2% Triton/DEPC-PBS for 10 minutes and dehydrated 
with 70%, 90% and 100% ethanol and desiccant chamber. After 
being air-dried, a pre-hybridization with 50% formamide/50 mmol/L 
sodium phosphate buffer/10% dextran sulphate/2X saline-sodium 
citrate (SSC) buffer for 1 hour at 66°C was performed. The probe 
was denatured in hybridization buffer for 75 seconds at 80°C, and 
40 nmol/L was added to 200 μL of pre-hybridization buffer for each 
slide. Hybridization was performed in a humidified chamber for 
20 hours at 66°C. Slides were washed once in 2X SSC/0.1% Tween 
20 and then three times in 0.1X SSC before being ethanol dehydrated 
and mounted with ProLong Gold anti-fade reagent with DAPI. Images 
were acquired by confocal microscope and analyses of foci performed 
with ImageJ software.
2.9 | Southern Blot
For Southern Blot (SB) analysis, a 32P-radioactive C9ORF72 probe 
466bp-long up-stream the repeat expansion was obtained with the 
following primers: FOR: 5′CTTTCTCCAGATCCAGCAGCCTCC3′ 
and REV: 5′CTGAGTTCCAGAGCTTGCTACAG3′. A total amount of 
9 μg of genomic DNA was digested overnight at 37°C with 50 U of 
XbaI restriction enzyme and 1% BSA. The day after, digested DNA 
and molecular weights (MW 1 kb and XV) were loaded on a 0.7% 
agarose gel in TBE and electrophoresed for 2 hours at 70 V and over-
night at 40 V. On the third day, gel was washed in HCl 0.25 N, gently 
shaken for 20 minutes to break the DNA into smaller fragments and 
enhance the transfer onto hybridization membrane. DNA was then 
transferred to a positively charged nylon membrane (Amersham 
Hybond-N+, GE Healthcare) by capillary blotting overnight and 
cross-linked by UV irradiation. After pre-hybridization at 42°C for 
6 hours, hybridization with the specific probe was carried out at 
42°C overnight. The membrane was then washed in 2XSSC/0.1% 
sodium dodecyl sulphate (SDS) at room temperature for 20 minutes 
and in 0.5X SSC/0.1% SDS at 60°C for 15 minutes. After a brief wash 
in SSC 0.1X, the dried blot was placed in the film cassette with the 
auto-radiographic film and exposed for at least two nights at −20°C 
before developing.
2.10 | Sodium arsenite treatment and stress 
granules evaluation
MNs were seeded on coverslips at a concentration of 10 × 105 cells/
well and on day 10 exposed to 0.5 mmol/L sodium arsenite (Merck). 
After 1 hour of treatment, cells were fixed for immunocytochemis-
try. The presence of stress granules was revealed by immunofluo-
rescence as previously described using a specific anti-TIAR-1 (1:300, 
Cell Signaling Technology) antibody.
2.11 | Quantification and statistical analyses
Bar charts represent the mean ± standard error mean (SEM). 
Statistical differences were assessed by Fisher's exact test and t test. 
A P value of <.05 was considered significant.
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3  | RESULTS
3.1 | No differences were observed between FB- 
and PB-derived iPSCs regarding their reprogramming 
potential and stemness
We found no differences in the reprogramming efficiency com-
paring the two different cell sources. Both cell types gave rise to 
more than 12 emerging colonies after reprogramming and 6 clones 
for each source were picked and showed the same expansion rate. 
iPSCs clones from both tissues formed compact colonies, present-
ing cells with high nucleus/cytoplasm ratio and distinct colony 
border. Colonies were able to be maintained over 50 passages and 
transgene vectors were lost within the first five passages, as shown 
in Figure 1C. iPSCs were subjected to a standard cytogenetic pro-
cedure to ascertain their normal karyotype (Figure 1A), and the 
maintenance of the C9ORF72 expansion was established by repeat 
primed PCR (Figure 1B).
To ensure their stemness, expression of specific intracellular 
markers was evaluated by RT-PCR (Sox 2, Oct 3/4 and Nanog) and 
by immunofluorescence (SSEA-4, TRA-1-60 and alkaline phospha-
tase). Expression of early transcription factors, absent or weakly 
detectable in starting tissues, confirmed staminality of our iPSCs 
(Figure 1D). Additionally, both samples showed positivity for the 
expression of stemness proteins (Figure 1E). We conducted plurip-
otency assays of the clones, assessing their ability to spontaneously 
differentiate into cells of the three germ layers. iPSCs formed spher-
ical embryoid bodies (EBs) when cultured in suspension for 7 days 
in non-adherent dishes. Once allowed to adhere on Matrigel-coated 
dishes, EBs from both clones spontaneously differentiated into en-
dodermal (α-fetoprotein positive), ectodermal (β III tubulin positive) 
and mesodermal (positive for Desmin) cells (Figure 1F). Furthermore, 
if cultured in a specific neural induction medium, iPSCs changed 
their typical shape, becoming 100% positive for the neural stem/
progenitor cell marker nestin (Figure 1G) either way.
Given these data, during this preliminary characterization phase, 
no differences were observed between clones in terms of stemness 
properties, pluripotency and ability to differentiate into neural cells.
3.2 | FB- and PB-derived iPSCs displayed the same 
ability to differentiate into motor neurons
Upon cells characterization, in a second set of experiments we pro-
ceeded in evaluating the capability of one iPSC clone derived from 
FB and PB to differentiate into motor neurons (MNs). Cells were 
induced to differentiate into MNs within 10 days and then charac-
terized by RT-PCR and immunocytochemistry. Regardless of the cell 
source, iPSCs displayed the same ability to form EBs and to give rise 
to MNs (Figure 2A). Cells were stained to verify the positivity for dif-
ferent specific markers such as β III tubulin (neuronal microtubules), 
HB9 (MNs) and SMI312 (neurofilaments, pan axonal) (Figure 2A). 
All cells showed positive staining for β III tubulin and SMI312, while 
HB9 was present in a lower but comparable percentage of cells in 
both samples. In particular, an average number of 328 cells from two 
independent experiments was analysed, determining that the per-
centage of HB9 positive MNs was 29% (±14) and 26.9% (±8.3) for 
FB and PB, respectively (Figure 2B) (P value .79). Moreover, HB9 and 
choline acetyltransferase (Chat) mRNAs were expressed in both MN 
samples after differentiation but not in iPSCs, as revealed by RT-PCR 
(Figure 2C), confirming a successful neuronal commitment.
3.3 | C9ORF72 mutation-specific hallmarks were 
present in the same way in both iPSCs and iPSC-
derived MNs
We subsequently investigated some specific hallmarks of the 
C9ORF72 mutation. In particular, it is known that the presence of the 
G4C2-repeat expansion leads to the formation of nuclear and cyto-
plasmic RNA foci constituted by sense and antisense mutant intronic 
RNA. We confirmed the presence of cells forming sense foci in our 
iPSCs and iPSC-derived MNs, evaluating by fluorescence in situ hy-
bridization (FISH) the number of cells forming foci and the number 
of foci per cell. Again in both samples analysed, no significant dif-
ferences were observed neither in the percentage of cells showing 
foci nor in the number of foci per cell (Figure 3A). Fisher's exact test 
statistic value is 0.1827 and 0.0894, respectively.
Variation of G4C2-repeat length can be detected among different 
tissues of the same individual. We found that the repeat size, evalu-
ated by Southern blot (SB) analysis, was originally different in PB and 
FB (Figure 3B, lane 1 and 4, respectively) of our patient, suggesting 
that intrinsic properties of specific tissue might affect the stability 
of the expanded repeats. Furthermore, once reprogrammed, we ob-
served a decrease in the number of G4C2-repeats in both PB- and 
FB-derived iPSCs (Figure 3B, lane 2 and 5, respectively) compared 
with the starting cells, remaining however within a range of patho-
logical size (higher than 30 repeats). Moreover, SB analysis revealed 
the presence of two different bands in both FB- and PB-derived 
iPSCs, with different sizes (430 and 150 repeats for FB; 2000 and 
800 repeats for PB).
3.4 | A prevalent nuclear localization of TDP-43 
protein is shown in both iPSC-derived MNs
The presence of cytoplasmic aggregates of the TDP-43 protein is 
another common neuropathological hallmark, even if FB and iPSCs 
derived from ALS and FTD patients do not display the character-
istic aggregates observed in affected brains. To deepen our char-
acterization, we investigated the presence and the localization of 
TDP-43 protein. Immunocytochemistry of both iPSC-derived MNs 
revealed that TDP-43 was localized almost totally within the nucleus 
with few cells displaying cytoplasmic mislocalization of the protein. 
In particular, an average number of 483 cells from two independ-
ent experiments was analysed, determining that the percentage 
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F I G U R E  1   Characterization of induced pluripotent stem cells (iPSCs). A, Q-banding karyotype of FB and PB-derived iPSCs. B, Repeat 
primed PCR of iPSCs from FB and PB to confirm the G4C2-repeat expansion. C, RT-PCR analysis for the transgene KOS, Klf4, c-Myc and 
SeV performed on FB-iPSCs and PB-iPSCs after the fifth passage. Reprogrammed FB were used as positive control. RPL10a was used as 
loading control. D, Expression of iPSC specific markers Sox 2, Oct 3/4 and Nanog assessed by RT-PCR on starting tissues (FB and PB), iPSCs 
and positive control (other iPSC line). E, Representative images of iPSC colonies derived from FB and PB stained for the stemness markers 
SSEA-4, TRA-1-60 and alkaline phosphatase (Alk Phosph). F, Differentiated EBs spontaneously generated cells of the three germ layers: 
endoderm (α-feto protein positive), ectoderm (β III tubulin positive) and mesoderm (desmin positive). G, Representative images of iPSC lines 
differentiated towards neural fate. iPSCs differentiated for 7 days in induction medium and expanded for five passages in expansion 
medium became nestin positive. Nuclei were counterstained with DAPI. Scale bars, 100 μm. Images are representative of 1-2 independent 
experiments
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of iPSC-derived MNs displaying a cytoplasmic mislocalization of 
TDP-43 was 8% (±2.9) and 6.22% (±3.4) (P value .56) for FB and PB, 
respectively (Figure 3C). Similarly, neither mislocalization nor aggre-
gates were observed using an anti-phospho TDP-43 antibody (data 
not shown).
On the other hand, the total amount of TDP-43, evaluated by 
Western blot (WB), was comparable between FB- and PB-derived 
iPSCs and between iPSC-derived MNs of both tissues. Higher levels 
of the protein were observed in MNs vs iPSCs in both models (1.5 
and 1.6-fold increase for FB and PB, respectively) (Figure 3D).
3.5 | iPSC-derived MNs produce stress granules 
following acute oxidative stress treatment
ALS-related proteins are also involved in stress granules dynamics, a 
highly adaptive mechanism built up in response to stressful environ-
mental insults. To mimic acute stress conditions in vitro, we treated 
iPSC-derived MNs at day 10 of differentiation with 0.5 mmol/L 
sodium arsenite for 1 hour and analysed cell responses. Following 
acute exposure to sodium arsenite, both iPSC-derived MNs were 
able to produce TIAR positive stress granules in the 100% of the 
cells as adaptive mechanism (Figure 3E, with magnification panels). 
No differences were found in terms of number of stress granules 
formed by both samples (average number of 2.5 granules/cell for FB 
vs 2.2 granules/cell for PB, 80 cells/sample analysed).
4  | DISCUSSION
This is a proof-of-principle study aimed to compare FB- and PB-
derived iPSCs from the same individual.
In particular, our aim was to investigate the key aspects of iPSCs 
and iPSC-derived MNs obtained from both FB and PB of a C9ORF72-
mutated patient to establish their comparability. Differentiation of 
human neural progenitor cells from iPSCs has been already demon-
strated to occur similarly regardless their somatic tissue origin.14 
However, a comparison of iPSC-derived MNs from two tissues of 
the same C9ORF72-mutated ALS patient has never been performed. 
The C9ORF72 mutation was chosen in this study as the most com-
mon genetic cause of ALS and FTD,15,16 two fatal neurodegenerative 
diseases. In addition, patient cells carrying this mutation exhibit well 
known specific pathogenic molecular hallmarks that can be explored, 
such as RNA foci and repeat expansion length. In our work, initial 
F I G U R E  2   Comparison of C9ORF72-
mutated iPSC-derived motor neurons. A, 
iPSCs from FB and PB were induced to 
generate embryoid bodies (EBs). After 
this first step, EBs were dissociated and 
differentiated into motor neurons (MNs). 
MNs were stained with the specific 
nuclear HB9 antigen (red) and co-stained 
with the microtubule-specific marker 
β III tubulin (green). The positivity for 
the pan-axonal neurofilament marker 
SMI312 was also assessed (red). Nuclei 
were counterstained with DAPI. Scale 
bar, 20 µm. B, Histogram displaying 
the percentage of HB9 positive cells 
in iPSC-derived MNs from FB and PB. 
C, Expression of MNs-specific markers 
Chat and HB9 evaluated by RT-PCR on 
both iPSCs (lanes 1 and 3) and iPSC-
derived MNs (lanes 2 and 4). Images 
are representative of 1-2 independent 
experiments
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characterization studies of iPSCs showed no differences between 
the clones investigated in terms of stemness properties, markers ex-
pression, pluripotency and ability to differentiate into neural cells 
demonstrating that iPSCs obtained from FB and PB show equivalent 
characteristics. This was also true for the iPSCs differentiation into 
MNs. Clones displayed the same ability to differentiate into β III tu-
bulin/SMI312 positive MNs, presenting a similar percentage of HB9 
expressing cells.
The presence of the G4C2-repeat expansion in the noncoding re-
gion of the C9ORF72 gene leads to a C9ORF72-reduced expression, 
suggesting haploinsufficiency as one of the potential disease-causing 
mechanisms.17 Additional specific pathological hallmark of C9ORF72 
patients is represented by the presence of nuclear and cytoplasmic 
RNA foci formed by sense and antisense G4C2-repeat transcripts
12,18 
as well as accumulation of five different dipeptide repeat proteins 
(DPRs) generated by mean of a repeat-associated non-AUG (RAN) 
translation, mostly in the neuron cytoplasm.19 Previous reports have 
already demonstrated the presence of both RNA foci and DPRs in 
C9ORF72-mutated iPSC-derived MNs.20,21 In this study, we quanti-
fied the number of cells showing foci and also the number of foci per 
cell in our iPSCs and iPSC-derived MNs without finding statistically 
significant differences among all samples.
The G4C2-repeat expansion was confirmed by both primed PCR 
and SB analyses in our FB- and PB-derived iPSCs. In this study, not 
surprisingly, the two tissues displayed different sizes of the repeat 
expansion. Indeed, intra-individual dissimilarity of number of repeats 
between tissues has already been described.22 In addition, after re-
programming, we observed a contraction in the size of the expan-
sion in both samples. It is conceivable that this contraction, probably 
caused by reprogramming, is due to a selection of clones with a less 
extended repeat length and therefore higher stability. Furthermore, 
SB analysis revealed the presence of two expansions of different 
sizes in both iPSC samples. Considering the clonal origin of iPSCs, 
this result appears unexpected and could reflect a mosaicism that 
probably occurred during expansion of iPSCs. In fact, instability of 
expanded repeats depending on the passage number of iPSCs has 
already been reported for iPSCs derived from a patient affected by 
myotonic dystrophy type I, another disease caused by expanded 
repeat.23 The presence of clones with different sizes of expansion 
should be taken in consideration for further applicative studies.
Regarding another hallmark of ALS pathology, no pathological 
protein aggregates but a slight cytoplasmic mislocalization of the 
TDP-43 protein were observed, in contrast to what is found in 
post mortem ALS patient MNs. Nevertheless, similar discrepancies 
between in vivo and in vitro cells were already been reported.13 
Results from previous studies investigating the presence of TDP-43 
protein pathological phenotype in iPSC-derived MNs vary consid-
erably from one to the other. Burkhardt et al24 identified nuclear 
aggregates in 3 out 24 reprogrammed skin fibroblasts from sporadic 
ALS patients. Similarly, two authors reported cytoplasmic pre-in-
clusion-like aggregates on MNs derived from TDP-43-mutated 
patients25,26 while no aggregation was observed in two other stud-
ies.13,27 No subcellular localization was observed for TDP-43 pro-
tein in iPSCs20 and iPSC-derived MNs21 from C9ORF72-mutated 
patients while nuclear depletion and cytoplasmic accumulation of 
the protein were reported by Zhang et al.28 The total amount of the 
TDP-43 protein evaluated by WB was comparable between FB- and 
PB-derived iPSCs and between iPSC-derived MNs of both tissues, 
with a slight increase in MNs. This can be probably due to a higher 
metabolism and protein translation of the differentiated cells if com-
pared to iPSCs.
No differences were found in the response to acute stress pro-
voked by sodium arsenite treatment. Both iPSC-derived MNs were 
able to produce TIAR positive stress granules as adaptive mechanism 
to stressful environmental insults.
5  | CONCLUSION
iPSCs and iPSC-derived MNs represent powerful patient-specific 
models to investigate pathological mechanisms in diseases such 
as ALS and FTD. In this study, for the first time, we demonstrated 
that reprogrammed cells from PB are fully comparable with repro-
grammed FB, underling that the cell source does not affect iPSC 
peculiarities, differentiation potential and specific pathological fea-
tures. For some diseases, such as rare or childhood pathologies, dif-
ferent types of tissue may be available from different patients and 
we have successfully demonstrated that the resulting iPSCs can be 
compared anyway. Our findings represent new evidence, leading 
to develop promising tools for future translational and therapeutic 
applications.
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F I G U R E  3   Comparison of specific pathological hallmarks in FB- and PB-derived cells. A, The percentage of cells with foci and the number 
of foci per cell were evaluated in both iPSCs and iPSC-derived MNs by FISH technique. Foci are indicated by head arrows. Scale bar, 5 µm. B, 
Southern blot analysis on DNA obtained from PB and FB (lanes 1 and 4) and PB- and FB-derived iPSCs (lanes 2 and 5). Sample from a healthy 
donor (negative control) is shown in lane 3. C, Motor neurons derived from FB- and PB-iPSCs were analysed to observe localization and 
aggregation of TDP-43 protein (green) by immunofluorescence. Cells were co-stained with the pan-axonal neurofilament marker SMI312 
(red). Scale bar, 20 µm. Magnification of cells displaying a cytoplasmic mislocalization. D, Western blot analysis of the total amount of TDP-
43 protein in iPSCs (lanes 1 and 3) and iPSC-derived MNs (lanes 2 and 4). Densitometry analysis in lower panel: for both FB and PB-derived 
MNs, the expression was calculated using as reference the TDP-43 protein level of their corresponding iPSCs. E, Representative images of 
differentiated MNs following acute treatment with sodium arsenite (0.5 mmol/L, 1 h). After treatment, MNs were immunostained for the 
stress granule marker, TIAR1 (green) and the pan-axonal neurofilament marker SMI312 (red). Scale bar, 20 µm. Stress granules are indicated 
by head arrows in the magnification panels. MNs images are representative of two independent experiments
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